Pfizer announces a “drug of hope” to defeat Corona … and sets the date

0
26


The CEO of “Pfizer” announced, Tuesday, that the experimental drug produced by the company to treat Covid-19 by mouth, may be available by the end of the year.

In an interview with CNBC, Albert Burla added that if the clinical trials went well and the Food and Drug Administration approved the drug, it could be distributed throughout the United States by the end of the year.

Health experts say that the drug, which is taken orally at the onset of symptoms, can change the rules of the game, because people with the new virus can use it outside hospitals.

Pfizer, which developed with the German pharmaceutical company Biontech, the first vaccine against Covid-19 that was licensed for use in the United States, began in March an early phase of clinical trials to test a new antiviral treatment to counter Covid-19.

The drug, which is in the class of “protease inhibitors”, works by inhibiting an enzyme that the virus needs to multiply in human cells, and it is a technique used to treat other viral diseases, such as acquired immunodeficiency, “AIDS”, and viral hepatitis C.

While the initial efficacy test focuses on the early stage of infection in people, “Pfizer” also plans to explore whether the drug works to protect healthy people who have been exposed to the Corona virus, such as family members or roommates who live with an infected person.

Pfizer Kids Vaccine

Pfizer is still testing its vaccine on children between the ages of 6 months and 11 years, and public health officials and infectious disease experts say that vaccinating children is critical to ending the Coronavirus pandemic.

And earlier this month, the company asked the US Food and Drug Administration (FDA) to expand the license for the vaccine to allow its use to adolescents between the ages of 12 and 15 years.

During his interview with CNBC, Burla expressed optimism that the US Food and Drug Administration would approve the use of the vaccine to vaccinate teenagers.

");
//},3000);
}
});
//$(window).bind('scroll');
$(window).scroll(function () {
if (alreadyLoaded_facebookConnect == false) {
alreadyLoaded_facebookConnect = true;
// $(window).unbind('scroll');
// console.log(" scroll loaded");

(function (d, s, id) {
var js, fjs = d.getElementsByTagName(s)[0];
if (d.getElementById(id)) return;
js = d.createElement(s); js.id = id;
js.async = true;
js._https = true;
js.src = "https://connect.facebook.net/en_US/all.js#xfbml=1&appId=148379388602322";
fjs.parentNode.insertBefore(js, fjs);
}(document, 'script', 'facebook-jssdk'));
// pre_loader();
// $(window).unbind('mousemove');
//setTimeout(function(){
// $('#boxTwitter').html("");
//},3000);

var scriptTag = document.createElement("script");
scriptTag.type = "text/javascript"
scriptTag.src = "https://news.google.com/scripts/social.js";
scriptTag.async = true;
document.getElementsByTagName("head")[0].appendChild(scriptTag);

(function () {
$.getScript("https://news.google.com/scripts/social.js", function () { });
});

}
});

//$(window).load(function () {
// setTimeout(function(){
// // add the returned content to a newly created script tag
// var se = document.createElement('script');
// se.type = "text/javascript";
// //se.async = true;
// se.text = "setTimeout(function(){ pre_loader(); },5000); ";
// document.getElementsByTagName('body')[0].appendChild(se);
// },5000);
//});





LEAVE A REPLY

Please enter your comment!
Please enter your name here